Welcome to our dedicated page for Cogent Biosciences news (Ticker: COGT), a resource for investors and traders seeking the latest updates and insights on Cogent Biosciences stock.
Cogent Biosciences Inc. (NASDAQ: COGT) is a clinical-stage biotechnology company pioneering precision therapies for patients with genetically defined diseases. This dedicated news hub provides investors and researchers with essential updates on the company's innovative programs targeting systemic mastocytosis, GIST, and other mutation-driven conditions.
Access real-time information about bezuclastinib clinical trials, including the SUMMIT (NonAdvSM), APEX (AdvSM), and PEAK (GIST) studies. Stay informed on pipeline developments across Cogent's portfolio of selective kinase inhibitors, from FGFR2-targeted therapies to novel KRAS(ON) inhibitors in preclinical testing.
Our curated news collection features official press releases, regulatory filings, and scientific presentation updates. Key content categories include clinical trial milestones, research collaborations, and therapeutic development progress – all critical for understanding Cogent's position in the precision medicine landscape.
Bookmark this page for streamlined access to verified COGT updates. Investors can monitor the company's advancement of potentially transformative therapies while researchers track developments in mutation-specific treatment approaches.
Cogent Biosciences (Nasdaq: COGT) released updates for 2021 and guidance for 2022, highlighting progress in developing therapies for genetically defined diseases. In 2021, they initiated three late-stage clinical trials for bezuclastinib, targeting systemic mastocytosis and gastrointestinal stromal tumors. Preliminary data from the APEX trial is anticipated in early 2022. The formation of the Cogent Research Team aims to expand their pipeline of novel compounds. The company is set to host an R&D investor event in April 2022 to further discuss their research advancements.
Cogent Biosciences (Nasdaq: COGT) announced that CEO Andrew Robbins will participate in a fireside chat and one-on-one investor meetings at the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021. The pre-recorded chat will be available starting at 10:00 a.m. ET and accessible until the conference concludes. Cogent focuses on precision therapies for genetically defined diseases, with its lead program, bezuclastinib, targeting the KIT D816V mutation linked to systemic mastocytosis and advanced gastrointestinal stromal tumors.
Cogent Biosciences, a biotechnology firm, announced its Q3 2021 financial results on November 10, 2021. The company reported R&D expenses of $14.8 million, significantly up from $5.0 million in Q3 2020. Net loss for the quarter was $19.1 million, an improvement compared to $50.0 million a year prior. Cash and cash equivalents as of September 30, 2021, stood at $202.9 million, sufficient to fund operations into 2024. The SUMMIT trial for bezuclastinib in systemic mastocytosis has begun, with other trials anticipated in 2022.
Cogent Biosciences, Inc. (Nasdaq: COGT) announced participation in the Jefferies London Healthcare Conference on November 18-19, 2021. CEO Andrew Robbins will engage in a fireside chat and one-on-one investor meetings. The chat starts at 4:00 AM ET on November 18 and can be accessed until 2:00 PM ET on November 19. Attendees can find the recording under the 'Events' tab on the investor relations page. Cogent focuses on developing precision therapies for genetically defined diseases, with bezuclastinib targeting the KIT D816V mutation linked to serious conditions.
Cogent Biosciences (Nasdaq: COGT) announced promising preclinical data for bezuclastinib, a selective KIT inhibitor, at the AACR-NCI-EORTC Virtual Conference. The study highlighted bezuclastinib's effectiveness against specific KIT mutations while showing minimal brain penetration, reducing potential CNS-related side effects. The company aims to initiate three clinical trials for Advanced Systemic Mastocytosis (AdvSM), Non-Advanced Systemic Mastocytosis (NonAdvSM), and Gastrointestinal Stromal Tumors (GIST) by the end of 2021, indicating a focused approach to developing targeted treatments for genetically defined diseases.
Cogent Biosciences (Nasdaq: COGT) will present preclinical data on bezuclastinib at the AACR-NCI-EORTC Virtual International Conference from October 7-10, 2021. The poster titled 'Preclinical data identifies bezuclastinib as a differentiated KIT inhibitor with unique selectivity to KIT D816V' will be available on their website shortly after 9:00 am ET on October 7.
Bezuclastinib targets the KIT D816V mutation related to systemic mastocytosis and various gastrointestinal stromal tumors. This research aims to enhance treatment options for patients with genetically driven diseases.
Cogent Biosciences (Nasdaq: COGT) announced its financial results for Q2 2021, reporting a net loss of $16.5 million, compared to $7.4 million in Q2 2020. R&D expenses surged to $12.4 million from $5.1 million year-over-year. The company initiated the Phase 2 APEX clinical study for bezuclastinib, targeting advanced systemic mastocytosis, and plans to start the SUMMIT study for non-advanced cases later in 2021. As of June 30, Cogent held $218.1 million in cash, sufficient to fund operations into 2024.
Cogent Biosciences (Nasdaq: COGT), a biotechnology firm focused on precision therapies for genetically defined diseases, will present at the Wedbush PacGrow Healthcare Conference on August 10, 2021, from 10:55 to 11:25 AM ET. CEO Andrew Robbins will lead the presentation. Attendees can access the live webcast and archived recording via the Cogent Biosciences investor relations website.
Cogent's lead therapy, bezuclastinib, targets KIT mutations linked to systemic mastocytosis and gastrointestinal stromal tumors.
Cogent Biosciences, Inc. (Nasdaq: COGT) announced that CEO Andrew Robbins will present at the Ladenburg Thalmann Virtual Healthcare Conference on July 14, 2021, from 2:00-2:25 pm ET. The event will highlight the company's focus on developing precision therapies for genetically defined diseases, including the clinical program for bezuclastinib, targeting the KIT D816V mutation linked to systemic mastocytosis and gastrointestinal stromal tumors. Interested parties can access the live webcast and archived recording through the Cogent Biosciences investor relations website.
Cogent Biosciences, Inc. (Nasdaq: COGT) announced that its CEO, Andrew Robbins, will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, from 11:30-11:55am ET. The company focuses on precision therapies for genetically defined diseases, with its lead program, CGT9486, targeting the KIT D816V mutation linked to systemic mastocytosis and gastrointestinal stromal tumors. Webcast access will be available on the Cogent investor relations website.
FAQ
What is the current stock price of Cogent Biosciences (COGT)?
What is the market cap of Cogent Biosciences (COGT)?
